{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:53:39Z","timestamp":1794538419751,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The maximum daily dose of follitropin delta for ovarian stimulation in the first in vitro fertilization cycle is 12\u2009\u03bcg (180\u2009IU), according to the algorithm developed by the manufacturer, and based on patient\u2019s ovarian reserve and weight. This study aimed to assess whether 150\u2009IU of menotropin combined with follitropin delta improves the response to stimulation in women with serum antimullerian hormone levels less than 2.1\u2009ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study involved a prospective intervention group of 44 women who received 12\u2009\u03bcg of follitropin delta combined with 150\u2009IU of menotropin from the beginning of stimulation and a retrospective control group of 297 women who received 12\u2009\u03bcg of follitropin delta alone during the phase 3 study of this drug. The inclusion and exclusion criteria and other treatment and follow-up protocols in the two groups were similar. The pituitary suppression was achieved by administering a gonadotropin-releasing hormone (GnRH) antagonist. Ovulation triggering with human chorionic gonadotropin or GnRH agonist and the option of transferring fresh embryos or using freeze-all strategy were made according to the risk of developing ovarian hyperstimulation syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Women who received follitropin delta combined with menotropin had higher estradiol levels on trigger day (2150\u2009pg\/mL vs. 1373\u2009pg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001), more blastocysts (3.1 vs. 2.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.003) and more top-quality blastocysts (1.8 vs. 1.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.017). No difference was observed in pregnancy, implantation, miscarriage, and live birth rates after the first embryo transfer. The incidence of ovarian hyperstimulation syndrome did not differ between the groups. However, preventive measures for the syndrome were more frequent in the group using both drugs than in the control group (13.6% vs. 0.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In women with serum antimullerian hormone levels less than 2.1\u2009ng\/mL, the administration of 150\u2009IU of menotropin combined with 12\u2009\u03bcg of follitropin delta improved the ovarian response, making it a valid therapeutic option in situations where ovulation triggering with a GnRH agonist and freeze-all embryos strategy can be used routinely.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      U1111-1247-3260 (Brazilian Register of Clinical Trials, available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ensaiosclinicos.gov.br\/rg\/RBR-2kmyfm\">https:\/\/ensaiosclinicos.gov.br\/rg\/RBR-2kmyfm<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12958-023-01172-9","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T02:02:06Z","timestamp":1704160926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Follitropin delta combined with menotropin in patients at risk for poor ovarian response during in vitro fertilization cycles: a prospective controlled clinical study"],"prefix":"10.1186","volume":"22","author":[{"given":"Oscar Barbosa","family":"Duarte-Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Hideki","family":"Miyadahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Yugo Shiguehara","family":"Yamakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Bussadori","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Podgaec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0306-3356(21)00142-4","volume":"12","author":"SG Hillier","year":"1985","unstructured":"Hillier SG, Afnan AM, Margara RA, Winston RM. Superovulation strategy before in vitro fertilization. Clin Obstet Gynaecol. 1985;12:687\u2013723.","journal-title":"Clin Obstet Gynaecol"},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1210\/er.2005-0015","volume":"27","author":"NS Macklon","year":"2006","unstructured":"Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170\u2013207.","journal-title":"Endocr Rev"},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003495-200464030-00005","volume":"64","author":"JA Huirne","year":"2004","unstructured":"Huirne JA, Lambalk CB, van Loenen AC, Schats R, Hompes PG, Fauser BC, et al. Contemporary pharmacological manipulation in assisted reproduction. Drugs. 2004;64:297\u2013322.","journal-title":"Drugs."},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EC-17-0067","volume":"6","author":"W Koechling","year":"2017","unstructured":"Koechling W, Plaksin D, Croston GE, Jeppesen JV, Macklon KT, Andersen CY. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect. 2017;6:297\u2013305.","journal-title":"Endocr Connect"},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/humrep\/dex219","volume":"32","author":"S Iliodromiti","year":"2017","unstructured":"Iliodromiti S, Salje B, Dewailly D, Fairburn C, Fanchin R, Fleming R, et al. Non-equivalence of anti-M\u00fcllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualized gonadotropin dosing. Hum Reprod. 2017;32:1710\u20135.","journal-title":"Hum Reprod"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/medicina57040379","volume":"57","author":"B Doroftei","year":"2021","unstructured":"Doroftei B, Ilie OD, Dabuleanu AM, Diaconu R, Maftei R, Simionescu G, et al. Follitropin Delta as a state-of-the-art incorporated companion for assisted reproductive procedures: a two year observational study. Medicina (Kaunas). 2021;57:379.","journal-title":"Medicina (Kaunas)"},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BC, Garc\u00eda-Velasco JA, Klein BM, Arce JC. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387\u201396.e4.","journal-title":"Fertil Steril"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.rbmo.2020.07.006","volume":"41","author":"JC Arce","year":"2020","unstructured":"Arce JC, Larsson P, Garc\u00eda-Velasco JA. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU\/day follitropin alfa. Reprod BioMed Online. 2020;41:616\u201322.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR9","first-page":"CD012693","volume":"2","author":"SF Lensen","year":"2018","unstructured":"Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al. Individualized gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilization plus intracytoplasmic sperm injection (IVF\/ICSI). Cochrane Database Syst Rev. 2018;2:CD012693.","journal-title":"Cochrane Database Syst Rev"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1472-6483(11)60007-2","volume":"22","author":"C Alviggi","year":"2011","unstructured":"Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Who needs LH in ovarian stimulation? Reprod BioMed Online. 2011;22:S33\u201341.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/humrep\/det045","volume":"28","author":"NP Polyzos","year":"2013","unstructured":"Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, et al. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod. 2013;28:1254\u201360.","journal-title":"Hum Reprod"},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/09513590.2014.932342","volume":"30","author":"E Papaleo","year":"2014","unstructured":"Papaleo E, Vanni VS, Vigan\u00f2 P, La Marca A, Pagliardini L, Vitrano R, et al. Recombinant LH administration in subsequent cycle after \u201cunexpected\u201d poor response to recombinant FSH monotherapy. Gynecol Endocrinol. 2014;30:813\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"1172_CR13","first-page":"CD005070","volume":"5","author":"MH Mochtar","year":"2017","unstructured":"Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF\/ICSI cycles. Cochrane Database Syst Rev. 2017;5:CD005070.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1172_CR14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","volume":"26","author":"AP Ferraretti","year":"2011","unstructured":"Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616\u201324.","journal-title":"Hum Reprod"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1472-6483(10)60042-9","volume":"19","author":"A Golan","year":"2009","unstructured":"Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reprod BioMed Online. 2009;19:28\u201332.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135.","journal-title":"Cancer"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","volume":"206","author":"TC Wright Jr","year":"2012","unstructured":"Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206:46.e1\u201346.e11.","journal-title":"Am J Obstet Gynecol"},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: elegant graphics for data analysis. 1 ed","author":"H Wickham","year":"2009","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. 1 ed. New York, NY: Springer; 2009. p. 213."},{"key":"1172_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.rbmo.2017.06.015","volume":"35","author":"ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine","year":"2017","unstructured":"ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod BioMed Online. 2017;35:494\u2013510.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.fertnstert.2020.09.158","volume":"115","author":"F Bissonnette","year":"2021","unstructured":"Bissonnette F, Minano Masip J, Kadoch IJ, Librach C, Sampalis J, Yuzpe A. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil Steril. 2021;115:991\u20131000.","journal-title":"Fertil Steril"},{"key":"1172_CR22","doi-asserted-by":"publisher","first-page":"992677","DOI":"10.3389\/fendo.2022.992677","volume":"13","author":"C Blockeel","year":"2022","unstructured":"Blockeel C, Griesinger G, Rago R, Larsson P, Sonderegger YLY, Rivi\u00e8re S, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Front Endocrinol (Lausanne). 2022;13:992677.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1172_CR23","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/jcph.328","volume":"54","author":"H Olsson","year":"2014","unstructured":"Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014;54:1299\u2013307.","journal-title":"J Clin Pharmacol"},{"key":"1172_CR24","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","volume":"102","author":"JC Arce","year":"2014","unstructured":"Arce JC, Andersen AN, Fern\u00e1ndez-S\u00e1nchez M, Visnova H, Bosch E, Garc\u00eda-Velasco JA, et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antim\u00fcllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection. Fertil Steril. 2014;102:1633\u201340.e5.","journal-title":"Fertil Steril"},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/cen.12864","volume":"83","author":"E Bosch","year":"2015","unstructured":"Bosch E, Nyboe Andersen A, Barri P, Garc\u00eda-Velasco JA, de Sutter P, Fern\u00e1ndez-S\u00e1nchez M, et al. Follicular and endocrine dose responses according to anti-M\u00fcllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049). Clin Endocrinol. 2015;83:902\u201312.","journal-title":"Clin Endocrinol"},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.rbmo.2017.01.010","volume":"34","author":"MM Alper","year":"2017","unstructured":"Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? Reprod BioMed Online. 2017;34:345\u201353.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10815-015-0599-7","volume":"32","author":"Z Blumenfeld","year":"2015","unstructured":"Blumenfeld Z. Why more is less and less is more when it comes to ovarian stimulation. J Assist Reprod Genet. 2015;32:1713\u20139.","journal-title":"J Assist Reprod Genet"},{"key":"1172_CR28","first-page":"336","volume":"21","author":"E Borges Jr","year":"2017","unstructured":"Borges E Jr, Zanetti BF, Setti AS, Braga DP, Figueira RCS, Iaconelli A Jr. FSH dose to stimulate different patients\u2019 ages: when less is more. JBRA Assist Reprod. 2017;21:336\u201342.","journal-title":"JBRA Assist Reprod"},{"key":"1172_CR29","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.fertnstert.2007.05.055","volume":"89","author":"L Pal","year":"2008","unstructured":"Pal L, Jindal S, Witt BR, Santoro N. Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril. 2008;89:1694\u2013701.","journal-title":"Fertil Steril"},{"key":"1172_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","volume":"38","author":"E Bosch","year":"2019","unstructured":"Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind phase 3 safety trial. Reprod BioMed Online. 2019;38:195\u2013205.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR31","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.3892\/mmr.2015.3904","volume":"12","author":"S Gizzo","year":"2015","unstructured":"Gizzo S, Andrisani A, Noventa M, Manfe S, Oliva A, Gangemi M, et al. Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: a cross-matched pilot investigation of the optimal daily dose and timing. Mol Med Rep. 2015;12:4219\u201329.","journal-title":"Mol Med Rep"},{"key":"1172_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/humrep\/deac246","volume":"38","author":"S Sperduti","year":"2023","unstructured":"Sperduti S, Paradiso E, Anzivino C, Lazzaretti C, Limoncella S, D'Alessandro S, et al. LH increases the response to FSH in granulosa-lutein cells from sub\/poor-responder patients in vitro. Hum Reprod. 2023;38:103\u201312.","journal-title":"Hum Reprod"},{"key":"1172_CR33","doi-asserted-by":"crossref","unstructured":"D'Angelo A, Amso NN, Hassan R. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2017;5(5):CD002811.","DOI":"10.1002\/14651858.CD002811.pub4"},{"key":"1172_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1477-7827-9-147","volume":"9","author":"EG Papanikolaou","year":"2011","unstructured":"Papanikolaou EG, Humaidan P, Polyzos N, Kalantaridou S, Kol S, Benadiva C, et al. New algorithm for OHSS prevention. Reprod Biol Endocrinol. 2011;9:147.","journal-title":"Reprod Biol Endocrinol"},{"key":"1172_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/14647273.2013.795385","volume":"16","author":"LG Nardo","year":"2013","unstructured":"Nardo LG, Bosch E, Lambalk CB, Gelbaya TA. Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil (Camb). 2013;16:144\u201350.","journal-title":"Hum Fertil (Camb)"},{"key":"1172_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.fertnstert.2012.05.019","volume":"98","author":"A Maheshwari","year":"2012","unstructured":"Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril. 2012;98:368\u201377.","journal-title":"Fertil Steril"},{"key":"1172_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.fertnstert.2013.03.038","volume":"100","author":"PE Levi Setti","year":"2013","unstructured":"Levi Setti PE, Albani E, Morenghi E, Morreale G, Delle Piane L, Scaravelli G, et al. Comparative analysis of fetal and neonatal outcomes of pregnancies from fresh and cryopreserved\/thawed oocytes in the same group of patients. Fertil Steril. 2013;100:396\u2013401.","journal-title":"Fertil Steril"},{"key":"1172_CR38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.rbmo.2021.03.002","volume":"42","author":"J Moreno-Sepulveda","year":"2021","unstructured":"Moreno-Sepulveda J, Espin\u00f3s JJ, Checa MA. Lower risk of adverse perinatal outcomes in natural versus artificial frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Reprod BioMed Online. 2021;42:1131\u201345.","journal-title":"Reprod BioMed Online"},{"key":"1172_CR39","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.fertnstert.2014.03.026","volume":"101","author":"KT Barnhart","year":"2014","unstructured":"Barnhart KT. Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple. Fertil Steril. 2014;101:1205\u20138.","journal-title":"Fertil Steril"},{"key":"1172_CR40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.fertnstert.2020.04.037","volume":"113","author":"R Wang","year":"2020","unstructured":"Wang R, Chen ZJ, Vuong LN, Legro RS, Mol BW, Wilkinson J. Large randomized controlled trials in infertility. Fertil Steril. 2020;113:1093\u20139.","journal-title":"Fertil Steril"},{"key":"1172_CR41","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.bpobgyn.2022.102306","volume":"86","author":"Z Wang","year":"2023","unstructured":"Wang Z, Cantineau AEP, Hoek A, van Eekelen R, Mol BW, Wang R. Live birth is not the only relevant outcome in research assessing assisted reproductive technology. Best Pract Res Clin Obstet Gynaecol. 2023;86:102306.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1172_CR42","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/humrep\/der106","volume":"26","author":"SK Sunkara","year":"2011","unstructured":"Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26:1768\u201374.","journal-title":"Hum Reprod"},{"key":"1172_CR43","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/humrep\/dez100","volume":"34","author":"YJ Law","year":"2019","unstructured":"Law YJ, Zhang N, Venetis CA, Chambers GM, Harris K. The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles. Hum Reprod. 2019;34:1778\u201387.","journal-title":"Hum Reprod"},{"key":"1172_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fertnstert.2018.04.039","volume":"110","author":"NP Polyzos","year":"2018","unstructured":"Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women. Fertil Steril. 2018;110:661\u201370.e1.","journal-title":"Fertil Steril"},{"key":"1172_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3389\/fendo.2018.00589","volume":"9","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index. Front Endocrinol (Lausanne). 2018;9:589.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01172-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01172-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01172-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:07:57Z","timestamp":1704204477000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01172-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01172-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3462889\/v1","asserted-by":"object"}]},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (Hospital Israelita Albert Einstein, CAAE19795519.4.0000.0071), is registered in the Brazilian Registry of Clinical Trials (UTN code: 1111-1247-3260) and was conducted in accordance with the norms and guidelines of the National Research Ethics Commission of the National Health Council of Brazil. All participants signed a written informed consent form before being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is an investigator-initiated study conducted with funding from Ferring Pharmaceuticals. The funder had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.Dr. Oscar Barbosa Duarte-Filho is a speaker at Ferring Pharmaceuticals in Brazil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}